Cardiac resynchronisation therapy for the treatment of heart failure
Summary
Cardiac resynchronisation therapy using a pacing device is recommended as a possible treatment for people with heart failure where all of the following circumstances apply.
They have moderate to severe symptoms of heart failure that are affecting their daily life, measuring class 3 or class 4 in th ...
Read the complete summary
Cardiac resynchronisation therapy using a pacing device is recommended as a possible treatment for people with heart failure where all of the following circumstances apply.
- They have moderate to severe symptoms of heart failure that are affecting their daily life, measuring class 3 or class 4 in the New York Heart Association classification system.
- Their heart is beating regularly but an electrocardiogram (ECG) shows that the electrical system of the heart is not working properly.
- The left ventricle of their heart is pumping out less than 35% of its normal amount of blood (called the left ventricular ejection fraction).
- They are taking the drug treatment that is most effective for them.
NICE has said that a different type of pacing device, containing a defibrillator, may be considered for people with heart failure if:
- Their heart failure is suitable for treatment with a pacing device – in other words, all the circumstances in the list above apply.
And it is also suitable for treatment with a device called an implantable cardioverter defibrillator.
Change to the funding direction
NICE has advised the Department of Health that, because the recommendations in this guidance require an increase in the number of cardiologists and clinical staff who are trained in CRT, and in the number of implantation centres, it will take 18 months for the NHS to be in a position to fully implement it.
The Department of Health has considered this advice and has decided to extend the direction requiring the NHS to fund treatments recommended in NICE technology appraisal guidance.
Full details of the amendment to the funding direction for this appraisal are available on the Department of Health's website at: http://www.dh.gov.uk/en/Publicationsandstatistics/Legislation/Directionsfromthesecretaryofstate/DH_4075685
hide
Guidance documents
Implementing this guidance
We will consult on our review plans for this guidance in July 2010